PAM
HZNP

Princeton Alpha Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Princeton Alpha Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-26,932
Closed -$488K – 954
2016
Q3 		$488K Buy
+26,932
New +$526K 0.09% 334

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Princeton Alpha Management's HZNP Position: Q4 2016 in Review

Princeton Alpha Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 26,932 shares — an estimated $488K sold.

Princeton Alpha Management first reported a position in HZNP in Q3 2016 and held it in 1 quarter. The position peaked at $488K in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

  • Princeton Alpha Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 26,932 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $488K.
  • Princeton Alpha Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $488K in Q3 2016.
  • 234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Princeton Alpha Management's 13F filing for Q4 2016, filed 10 Feb 2017.